The much-anticipated initial public offering (IPO) of Senores Pharmaceuticals is set to open for public subscription on Friday, December 20, 2024, and will conclude on Tuesday, December 24, 2024. This book-built issue comprises a fresh issue of ₹500 crore and an offer for sale (OFS) of 21 lakh shares, offering investors an opportunity to tap into the growth story of a globally recognized pharmaceutical company.
Key Details of the IPO
Senores Pharmaceuticals IPO Schedule
- Opening Date: December 20, 2024.
- Closing Date: December 24, 2024.
- Listing Date: Expected on Monday, December 30, 2024, following the T+3 settlement rule.
IPO Price Band
The company is yet to announce the price band for the issue. Investors can expect the details in the coming days.
Book-Running Lead Managers
The IPO is being managed by Equirus Capital Private Limited, Ambit Private Limited, and Nuvama Wealth Management Limited.
IPO Registrar
The registrar for the issue is Link Intime India Private Limited, responsible for handling share allocation and refund processes.
Utilization of Funds
Senores Pharmaceuticals plans to utilize the net proceeds from the IPO for several strategic objectives, including:
- Subsidiary Investments: Strengthening its global presence by investing in its subsidiaries.
- Debt Reduction: Paying off existing borrowings to improve financial stability.
- Acquisitions and Strategic Initiatives: Exploring growth opportunities through acquisitions and expansions.
- General Corporate Purposes: Supporting its day-to-day operations and other business requirements.
About Senores Pharmaceuticals
A Global Pharmaceutical Leader
Senores Pharmaceuticals is a research-driven pharmaceutical company specializing in the development and manufacturing of a diverse range of pharmaceutical products. Its portfolio includes critical care injectables, APIs (Active Pharmaceutical Ingredients), and other formulations.
Global Reach
The company caters to highly regulated markets such as the US, Canada, and the United Kingdom, along with an established presence in emerging markets.
Financial Performance
Senores Pharmaceuticals has shown robust growth in recent years:
- Revenue:
- FY22: ₹141.70 million
- FY23: ₹353.37 million
- FY24: ₹2,145.24 million
- H1 FY25 (as of September 30, 2024): ₹1,810.18 million
- Profit:
- FY22: ₹9.91 million
- FY23: ₹84.33 million
- FY24: ₹327.08 million
- H1 FY25: ₹239.43 million
A Promising Investment Opportunity
With a strong growth trajectory, global market presence, and strategic plans for expansion, Senores Pharmaceuticals IPO offers a compelling opportunity for investors. Stay tuned for the announcement of the price band and further updates as the company gears up for its market debut on December 30, 2024.
Mark your calendars and prepare to evaluate this exciting IPO!
